Lobeglitazone, a Novel Thiazolidinedione, Improves Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: Its Efficacy and Predictive Factors Related to Responsiveness

Lee, Yong-ho; Kim, Jae Hyeon; Kim, So Ra; Jin, Heung Yong; Rhee, Eun-Jung; Cho, Young Min; Lee, Byung-Wan

To investigate whether any clinical and biochemical parameters were associated with lobeglitazone responsiveness, baseline characteristics of the study population were stratified by responsiveness (Table 1) , followed by two-step correlation and linear regression analyses with three statistical models of inde- (Tables 3 and 4 ). These analyses showed that the baseline CAP values were higher in patients who responded to lobeglitazone (320.9 ± 31.0 dB/m) than those who failed to respond (299.4 ± 26.3 dB/m) (P = 0.028). Other parameters did not show any association with lobeglitazone responsiveness. The first-step correlation analyses between changes in CAP values and various baseline parameters also demonstrated that patients with higher CAP values tended to have larger CAP decrements after lobeglitazone treatment (r = −0.434, P = 0.004).